| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6113527 | Critical Reviews in Oncology/Hematology | 2016 | 24 Pages |
Abstract
Evidence supports the notion that CINV continues to have a negative impact on HRQoL of patients, even for those receiving moderately emetic chemotherapy. Further studies need also to collect data on the cost of CINV, particularly indirect costs, to ensure that decisions on use of healthcare resources are better supported.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Silvia Sommariva, Benedetta Pongiglione, Rosanna Tarricone,